10-K - Interpace Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Interpace Biosciences reported $38.7M revenue with resilient 62.3% gross margins and $4.1M operating income, culminating in $24.6M net income driven by deferred tax asset realization that boosted diluted EPS to $0.89.

Key Takeaways

1Revenue totaled $38.7M as PancraGEN reimbursement loss after May 2025 halted specimen acceptance, per management discussion.

2Gross profit reached $24.1M at 62.3% margin, reflecting cost structure resilience amid revenue pressures.

3Operating income of $4.1M (10.5% margin) decreased primarily due to lower revenue and gross profit.

4Net income hit $24.6M with $0.89 diluted EPS, reflecting deferred tax asset release after annual realizability analysis.

Key Financial Metrics

EPS

$0.89

Revenue

$38.7M

Net Income

$24.6M

Gross Margin

62.3%

Gross Profit

$24.1M

free cash flow

$5.5M

Operating Income

$4.1M

operating margin

10.5%